SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC Drug Zibotentan Fails in Prostate Cancer Trial

September 27, 2010 | 
1 min read

LONDON, Sept 27 (Reuters) - AstraZeneca’s (AZN.L) experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to the company’s oncology pipeline.

Clinical research Phase III Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Colorful DNA molecule. Structure of the genetic code. Genetic Syndrome and Genetic Disorder, 3D illustration of science concept.
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
November 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Incyte's logo on its building in Delaware
Immunology and inflammation
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble
November 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An Eli Lilly Research Laboratories sign/
Cardiovascular disease
Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing
November 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
November 18, 2024
 · 
2 min read
 · 
Nick Paul Taylor